HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 44 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $2,672,000 | -49.7% | 1,052,093 | 0.0% | 0.01% | -36.4% |
| Q3 2018 | $5,313,000 | -41.3% | 1,052,093 | -62.1% | 0.01% | +10.0% |
| Q2 2018 | $9,048,000 | +136.7% | 2,775,766 | +162.8% | 0.01% | +11.1% |
| Q1 2018 | $3,823,000 | +1576.8% | 1,056,193 | +839.8% | 0.01% | – |
| Q4 2017 | $228,000 | +137.5% | 112,386 | +100.0% | 0.00% | – |
| Q3 2017 | $96,000 | -36.0% | 56,193 | -0.2% | 0.00% | – |
| Q2 2017 | $150,000 | -96.1% | 56,293 | -89.8% | 0.00% | -100.0% |
| Q1 2017 | $3,815,000 | +198.0% | 551,240 | -3.5% | 0.01% | +200.0% |
| Q4 2016 | $1,280,000 | -3.4% | 571,209 | +0.0% | 0.00% | 0.0% |
| Q3 2016 | $1,325,000 | -11.2% | 571,201 | -0.5% | 0.00% | -25.0% |
| Q2 2016 | $1,492,000 | -9.4% | 573,824 | +0.0% | 0.00% | 0.0% |
| Q1 2016 | $1,647,000 | -34.4% | 573,617 | -0.4% | 0.00% | -33.3% |
| Q4 2015 | $2,510,000 | -42.8% | 575,692 | 0.0% | 0.01% | -40.0% |
| Q3 2015 | $4,386,000 | -14.9% | 575,692 | +24.6% | 0.01% | 0.0% |
| Q2 2015 | $5,152,000 | – | 462,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PERKINS CAPITAL MANAGEMENT INC | 2,426,300 | $802,000 | 0.74% |
| Cowen Prime Services LLC | 1,411,500 | $466,000 | 0.23% |
| GSA CAPITAL PARTNERS LLP | 1,205,873 | $398,000 | 0.07% |
| Nantahala Capital Management | 5,113,958 | $1,690,000 | 0.05% |
| HighMark Wealth Management LLC | 80,000 | $26,000 | 0.02% |
| Kalos Management, Inc. | 72,858 | $24,000 | 0.01% |
| Qube Research & Technologies Ltd | 585,187 | $193,000 | 0.00% |
| WINTON GROUP Ltd | 190,146 | $63,000 | 0.00% |
| Ironwood Financial, llc | 1,571 | $1,000 | 0.00% |
| Virtu Financial LLC | 12,049 | $4,000 | 0.00% |